StageZero Life Sciences Ltd (SZLS) - Net Assets

Latest as of September 2024: CA$-11.13 Million CAD ≈ $-8.05 Million USD

Based on the latest financial reports, StageZero Life Sciences Ltd (SZLS) has net assets worth CA$-11.13 Million CAD (≈ $-8.05 Million USD) as of September 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$580.75K ≈ $420.11K USD) and total liabilities (CA$11.71 Million ≈ $8.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SZLS asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CA$-11.13 Million
% of Total Assets -1915.79%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change -530.58%
Growth Volatility 1567.77

StageZero Life Sciences Ltd - Net Assets Trend (1998–2022)

This chart illustrates how StageZero Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Also explore StageZero Life Sciences Ltd assets under control for the complete picture of this company's asset base.

Annual Net Assets for StageZero Life Sciences Ltd (1998–2022)

The table below shows the annual net assets of StageZero Life Sciences Ltd from 1998 to 2022. For live valuation and market cap data, see StageZero Life Sciences Ltd (SZLS) market capitalisation.

Year Net Assets Change
2022-12-31 CA$-7.50 Million
≈ $-5.43 Million		 -371.69%
2021-12-31 CA$2.76 Million
≈ $2.00 Million		 +323.90%
2020-12-31 CA$-1.23 Million
≈ $-892.28K		 +72.54%
2019-12-31 CA$-4.49 Million
≈ $-3.25 Million		 +7.14%
2018-12-31 CA$-4.84 Million
≈ $-3.50 Million		 -60.39%
2017-12-31 CA$-3.02 Million
≈ $-2.18 Million		 +36.21%
2016-12-31 CA$-4.73 Million
≈ $-3.42 Million		 -166.80%
2015-12-31 CA$-1.77 Million
≈ $-1.28 Million		 -182.26%
2014-12-31 CA$2.15 Million
≈ $1.56 Million		 +23.63%
2013-12-31 CA$1.74 Million
≈ $1.26 Million		 -65.63%
2012-12-31 CA$5.07 Million
≈ $3.67 Million		 +1676.89%
2011-12-31 CA$-321.56K
≈ $-232.61K		 -466.72%
2010-12-31 CA$87.69K
≈ $63.43K		 -96.48%
2009-12-31 CA$2.49 Million
≈ $1.80 Million		 +43.98%
2008-12-31 CA$1.73 Million
≈ $1.25 Million		 -87.48%
2007-12-31 CA$13.81 Million
≈ $9.99 Million		 -29.32%
2006-12-31 CA$19.54 Million
≈ $14.13 Million		 +229.49%
2005-12-31 CA$5.93 Million
≈ $4.29 Million		 -22.90%
2004-12-31 CA$7.69 Million
≈ $5.56 Million		 +34.00%
2003-12-31 CA$5.74 Million
≈ $4.15 Million		 +234.72%
2002-12-31 CA$1.71 Million
≈ $1.24 Million		 -25.13%
2001-12-31 CA$2.29 Million
≈ $1.66 Million		 -1.23%
2000-12-31 CA$2.32 Million
≈ $1.68 Million		 +6570.47%
1999-12-31 CA$34.76K
≈ $25.15K		 -78.98%
1998-12-31 CA$165.36K
≈ $119.62K		 --

Equity Component Analysis

This analysis shows how different components contribute to StageZero Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 12303005331.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2022)

Component Amount Percentage
Common Stock CA$101.39 Million %
Other Comprehensive Income CA$1.23 Million %
Other Components CA$12.91 Million %
Total Equity CA$-7.50 Million 100.00%

StageZero Life Sciences Ltd Competitors by Market Cap

The table below lists competitors of StageZero Life Sciences Ltd ranked by their market capitalization.

Company Market Cap
Yu Group PLC
LSE:YU
 $3.58 Million
Mexican Gold Corp
V:MEX
 $3.59 Million
Entreparticuli
PA:ALENT
 $3.59 Million
Euro Trend Yatirim Ortakligi AS
IS:ETYAT
 $3.59 Million
C29 Metals Ltd
AU:C29
 $3.57 Million
Ricky Putra Globalindo Tbk
JK:RICY
 $3.57 Million
ETRUSCUS RESOURCES CORP.
F:ERR
 $3.57 Million
Yari Minerals Ltd
AU:YAR
 $3.56 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in StageZero Life Sciences Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2021 to 2022, total equity changed from 2,761,765 to -7,503,337, a change of -10,265,102 (-371.7%).
  • Net loss of 11,415,372 reduced equity.
  • Share repurchases of 1,542,550 reduced equity.
  • New share issuances of 1,542,548 increased equity.
  • Other comprehensive income decreased equity by 70,714.
  • Other factors increased equity by 1,220,986.

Equity Change Factors (2021 to 2022)

Factor Impact Contribution
Net Income CA$-11.42 Million -152.14%
Share Repurchases CA$1.54 Million -20.56%
Share Issuances CA$1.54 Million +20.56%
Other Comprehensive Income CA$-70.71K -0.94%
Other Changes CA$1.22 Million +16.27%
Total Change CA$- -371.69%

Book Value vs Market Value Analysis

This analysis compares StageZero Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1998-12-31 CA$4.13 CA$0.04 x
1999-12-31 CA$0.87 CA$0.04 x
2000-12-31 CA$6.79 CA$0.04 x
2001-12-31 CA$6.01 CA$0.04 x
2002-12-31 CA$3.45 CA$0.04 x
2003-12-31 CA$9.48 CA$0.04 x
2004-12-31 CA$9.77 CA$0.04 x
2005-12-31 CA$6.77 CA$0.04 x
2006-12-31 CA$17.93 CA$0.04 x
2007-12-31 CA$11.21 CA$0.04 x
2008-12-31 CA$1.40 CA$0.04 x
2009-12-31 CA$1.88 CA$0.04 x
2010-12-31 CA$0.06 CA$0.04 x
2011-12-31 CA$-0.17 CA$0.04 x
2012-12-31 CA$2.22 CA$0.04 x
2013-12-31 CA$0.41 CA$0.04 x
2014-12-31 CA$0.36 CA$0.04 x
2015-12-31 CA$-0.27 CA$0.04 x
2016-12-31 CA$-0.57 CA$0.04 x
2017-12-31 CA$-0.25 CA$0.04 x
2018-12-31 CA$-0.28 CA$0.04 x
2019-12-31 CA$-0.13 CA$0.04 x
2020-12-31 CA$-0.03 CA$0.04 x
2021-12-31 CA$0.04 CA$0.04 x
2022-12-31 CA$-0.08 CA$0.04 x

Capital Efficiency Dashboard

This dashboard shows how efficiently StageZero Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -300.79%
  • • Asset Turnover: 5.42x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-354.40%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1998 -3.74% -950721.54% 0.00x 1.02x CA$-22.72K
1999 -954.42% -488.58% 1.78x 1.10x CA$-335.27K
2000 -48.83% -174217821.54% 0.00x 1.03x CA$-1.36 Million
2001 -59.47% 0.00% 0.00x 1.07x CA$-1.59 Million
2002 -50.62% -572.48% 0.07x 1.20x CA$-1.04 Million
2003 -4.61% -9.10% 0.46x 1.09x CA$-838.35K
2004 -60.75% -252.25% 0.14x 1.71x CA$-5.44 Million
2005 -44.65% -57.60% 0.52x 1.48x CA$-3.24 Million
2006 -39.23% -272.16% 0.13x 1.08x CA$-9.62 Million
2007 -70.44% -444.43% 0.12x 1.38x CA$-11.11 Million
2008 -625.72% -926.34% 0.20x 3.46x CA$-11.00 Million
2009 -214.51% -488.19% 0.17x 2.55x CA$-5.59 Million
2010 -5490.81% -2488.45% 0.04x 56.97x CA$-4.82 Million
2011 0.00% -4445.35% 0.02x 0.00x CA$-4.36 Million
2012 -100.18% -1804.08% 0.03x 1.98x CA$-5.59 Million
2013 -506.95% -7120.02% 0.04x 1.72x CA$-9.01 Million
2014 -306.83% -312.89% 0.72x 1.36x CA$-6.83 Million
2015 0.00% -1846.73% 0.57x 0.00x CA$-5.84 Million
2016 0.00% -560.76% 0.31x 0.00x CA$-5.44 Million
2017 0.00% -715.96% 0.15x 0.00x CA$-2.65 Million
2018 0.00% -2121.82% 0.07x 0.00x CA$-3.46 Million
2019 0.00% -3108.99% 0.07x 0.00x CA$-3.86 Million
2020 0.00% -173.04% 0.49x 0.00x CA$-7.06 Million
2021 -278.24% -151.62% 0.48x 3.85x CA$-7.96 Million
2022 0.00% -300.79% 5.42x 0.00x CA$-10.67 Million

Industry Comparison

This section compares StageZero Life Sciences Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $3,100,465
  • Average return on equity (ROE) among peers: -165.33%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
StageZero Life Sciences Ltd (SZLS) CA$-11.13 Million -3.74% N/A $3.58 Million
Avricore Health Inc (AVCR) $182.98K -29.23% 0.57x $5.13 Million
Spectral Med Inc (EDT) $5.43 Million -175.30% 0.56x $284.46 Million
Leveljump Healthcare Corp (JUMP) $6.20 Million 2.99% 0.98x $4.19 Million
Telo Genomics Corp (TELO) $590.06K -459.79% 0.64x $3.63 Million

About StageZero Life Sciences Ltd

TO:SZLS Canada Diagnostics & Research
Market Cap
$3.58 Million
CA$4.94 Million CAD
Market Cap Rank
#28949 Global
#1376 in Canada
Share Price
CA$0.04
Change (1 day)
+0.00%
52-Week Range
CA$0.04 - CA$0.04
All Time High
CA$4.16
Categories
Companies in Canada Diagnostics & Research
About

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more